Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells for Diabetic Foot
NCT02304588Phase 1Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2013
- Primary completion
- Dec 2015
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mesenchymal stem cells in diabetic foot disease (DFD) and limb ischemia, sponsored by Chinese PLA General Hospital. Primary endpoint: Frequency of Adverse Events at 6 months. Status: unknown.
02
Drugs
mesenchymal stem cells
03
Conditions
diabetic foot disease (DFD)limb ischemia
Beyond the preview
Go deeper on NCT02304588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02304588.